Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD

Condition(s) studied

Investigational drug(s) / intervention(s)

Placebo: Participants will breathe placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer

Treprostinil Inhalation Solution 36 mcg: Participants will breathe either 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer

Treprostinil Inhalation Solution 78 mcg: Participants will breathe either 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer

Study summary

The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to:

* Perform lung function and exercise tests
* Have ultrasound of their heart
* Have CT images of their lungs
* Visit the lab on 5 different occasions (plus one visit to the CT imaging clinic)

The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity

Eligibility

Primary outcome measure(s)

• Exercise tolerance — Within 30-45 minutes post dose
  Time to symptom limitation/exhaustion during a constant work rate test.
• Exertional dyspnea — Within 30-45 minutes post dose
  Maximal perceived breathing discomfort during exercise
• Ventilatory efficiency — Within 30-45 minutes post dose
  Nadir value of the ratio between ventilation and the rate of CO2 production (Ve/VCO2 nadir)

Trial sites (1)

More University of Alberta trials in Canada

Other trials for the same condition